Skip to content

Author

C. Bezzio

We have 2 of 44 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Sep 2026

Targeting IL-23p19 in Inflammatory Bowel Disease: The Road Ahead

Abstract Selective interleukin-23p19 (IL-23p19) inhibition represents a major advance in the management of inflammatory bowel disease (IBD). Risankizumab, mirikizumab, and guselkumab – three monoclonal antibodies targeting the p19 subunit of IL-23 – have each completed Phase 3 clinical development programs in both Croh...

Erica Bartolotta, G. Privitera, Arianna Dal Buono et al. · 0 citations
Open access Sep 2026

Real-World Effectiveness and Safety of Upadacitinib in Patients With Crohn's Disease-A Multicentre Prospective Study From the Italian Group for the Study of Inflammatory Bowel Diseases (IG-IBD).

Upadacitinib was effective and well-tolerated in AT-experienced Crohn's disease, including patients with active EIMs, with induction benefit maintained through 6 months without novel safety signals.

B. Barberio, F. D'Amico, L. Laterza et al. · 2 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.